Search results

The second health policy direction in the field of rare diseases is implemented using three measures: through the organization of personal healthcare service system; through the accessibility of healthcare services abroad and accessibility of medicines for patients suffering from rare diseases. It was concluded that personal healthcare service system for patients with rare diseases in Lithuania still does not work harmoniously. In order to improve the situation, it is proposed to revise the payment system currently functioning for the provision of personal healthcare services for the patients with rare diseases, as well to start the monitoring of rare diseases at the national scale. It has been determined that the legal regulations of the EU on cross-border provision of healthcare services to patients are implemented to the national law properly, however, the procedure related to the issue of permits for the patients to receive such services provides no specific exceptions for the patients with rare diseases. The analysis of legal regulation on the current accessibility to the medicine necessary to cure rare diseases states that Lithuania has conditions to supply orphan medicinal products to the Lithuanian market established. Essential weakness is that the so-called "compassionate use of medicinal products" has not been validated yet. The ethical problems are caused by the lack of reimbursement for orphan medicinal products, repeated procedures related to the evaluation of efficiency and therapeutic value of the orphan medicines at the national competent institutions.

The second health policy direction in the field of rare diseases is implemented using three measures: through the organization of personal healthcare service system; through the accessibility of healthcare services abroad and accessibility of medicines for patients suffering from rare diseases. It was concluded that personal healthcare service system for patients with rare diseases in Lithuania still does not work harmoniously. In order to improve the situation, it is proposed to revise the payment system currently functioning for the provision of personal healthcare services for the patients with rare diseases, as well to start the monitoring of rare diseases at the national scale. It has been determined that the legal regulations of the EU on cross-border provision of healthcare services to patients are implemented to the national law properly, however, the procedure related to the issue of permits for the patients to receive such services provides no specific exceptions for the patients with rare diseases. The analysis of legal regulation on the current accessibility to the medicine necessary to cure rare diseases states that Lithuania has conditions to supply orphan medicinal products to the Lithuanian market established. Essential weakness is that the so-called "compassionate use of medicinal products" has not been validated yet. The ethical problems are caused by the lack of reimbursement for orphan medicinal products, repeated procedures related to the evaluation of efficiency and therapeutic value of the orphan medicines at the national competent institutions.

The new position is that the services of necessary aid, which are funded by the state's budget funds, can be provided by private health care institutions only in exceptional situations. These aspects will have to be implemented by the relevant legislation of the Republic of Lithuanian in the near future. Analysis of the constitutional guarantees of Lithuanian nationals and other persons on receiving health care services, which are not considered as necessary medical aid, showed that compulsory health insurance in the constitutional doctrine is seen as the necessary system of funding health care services by public funds. The system is based on societal solidarity and allows ensuring sufficient accessibility of health care services. The current legal regulation lacks clarity, therefore, the paper offers setting clear limits of providing medical aid and, specifically, establishing the medical aid services that are not necessary for life and must be funded from the compulsory health insurance fund. It is also suggested to stipulate clearly, which health care services persons can receive, provided that they save the funds in voluntary health care fund (which practically does not function in Lithuania to this date), or otherwise they pay from their own funds to the health care institution. Each procedure for providing and paying for health care services must be regulated at the statutory level, considering the fundamental human right to life and good health.

The new position is that the services of necessary aid, which are funded by the state's budget funds, can be provided by private health care institutions only in exceptional situations. These aspects will have to be implemented by the relevant legislation of the Republic of Lithuanian in the near future. Analysis of the constitutional guarantees of Lithuanian nationals and other persons on receiving health care services, which are not considered as necessary medical aid, showed that compulsory health insurance in the constitutional doctrine is seen as the necessary system of funding health care services by public funds. The system is based on societal solidarity and allows ensuring sufficient accessibility of health care services. The current legal regulation lacks clarity, therefore, the paper offers setting clear limits of providing medical aid and, specifically, establishing the medical aid services that are not necessary for life and must be funded from the compulsory health insurance fund. It is also suggested to stipulate clearly, which health care services persons can receive, provided that they save the funds in voluntary health care fund (which practically does not function in Lithuania to this date), or otherwise they pay from their own funds to the health care institution. Each procedure for providing and paying for health care services must be regulated at the statutory level, considering the fundamental human right to life and good health.

The author establishes that the main condition of lawfulness of the restrictions of information about medicinal products is threat to human health as the protected personal and public value. This in particular applies to the advertisement of medicinal products. Other (not less important) criteria are: the social need (necessity), statutory regulation of restrictions of information provision, and their proportionality. Only objective is the non-misleading advertisement of registered, obtainable without prescription medicinal products, allowed through media that is accessible to patients in Lithuania. The issue of legal responsibility for patient information on medicinal products is analysed in the third part of the paper. The conclusions state that legal responsibility may arise as a result of advertisement of medicinal products and other products that are presented as such to patients that is not objective, is misleading, hidden, and infringes or fails to comply with statutory requirements. It may also arise in case of non-quality provision of pharmaceutical service, or non-ethical activities of health care and pharmacy specialists. Legal analysis of legislation revealed that the regulatory basis of provision of information on medicinal products in Lithuania has been created. However, there are still many gaps in this field, e.g., insufficiently defined advertisement of medicinal products, advertisement of food supplements, and mandatory civil liability of pharmacies is not established. There are also control deficiencies, e.g. hidden advertisement of medicinal products, and quality of pharmacy services.

The author establishes that the main condition of lawfulness of the restrictions of information about medicinal products is threat to human health as the protected personal and public value. This in particular applies to the advertisement of medicinal products. Other (not less important) criteria are: the social need (necessity), statutory regulation of restrictions of information provision, and their proportionality. Only objective is the non-misleading advertisement of registered, obtainable without prescription medicinal products, allowed through media that is accessible to patients in Lithuania. The issue of legal responsibility for patient information on medicinal products is analysed in the third part of the paper. The conclusions state that legal responsibility may arise as a result of advertisement of medicinal products and other products that are presented as such to patients that is not objective, is misleading, hidden, and infringes or fails to comply with statutory requirements. It may also arise in case of non-quality provision of pharmaceutical service, or non-ethical activities of health care and pharmacy specialists. Legal analysis of legislation revealed that the regulatory basis of provision of information on medicinal products in Lithuania has been created. However, there are still many gaps in this field, e.g., insufficiently defined advertisement of medicinal products, advertisement of food supplements, and mandatory civil liability of pharmacies is not established. There are also control deficiencies, e.g. hidden advertisement of medicinal products, and quality of pharmacy services.

Currently in Europe, approximately 30 million people suffer from rare diseases, and a major problem is that many patients do not have access to quality healthcare for their disorders. Moreover, there is also a lack of quality information and a networking system aimed at supporting interaction among patients, clinicians, researchers, pharmaceutical industries, and governmental bodies. The purpose of this article is to inform physicians, public health care professionals, and other health care providers about EuOrphan service, the aim of which is to ensure easier access to quality information on rare diseases and their treatment. A set of web-based services is available at www.euorphan.com where information for target-users on treatments and products available worldwide for rare disease care as well as indications about healthcare centers are provided. Moreover, the service aims at providing consultancies for pharmaceutical companies to ultimately support the European legislation in bringing new drugs of a high ethical standard to the market and to exert a positive impact on the large population of patients suffering from rare diseases in Europe. The services provided by EuOrphan can facilitate concrete networking among patients, patient associations, doctors, and companies and also support the organization of clinical trials. In this perspective, EuOrphan could become a very valuable tool for globalizing the information about the availability of treatment (authorized or under development) of orphan patients.

Currently in Europe, approximately 30 million people suffer from rare diseases, and a major problem is that many patients do not have access to quality healthcare for their disorders. Moreover, there is also a lack of quality information and a networking system aimed at supporting interaction among patients, clinicians, researchers, pharmaceutical industries, and governmental bodies. The purpose of this article is to inform physicians, public health care professionals, and other health care providers about EuOrphan service, the aim of which is to ensure easier access to quality information on rare diseases and their treatment. A set of web-based services is available at www.euorphan.com where information for target-users on treatments and products available worldwide for rare disease care as well as indications about healthcare centers are provided. Moreover, the service aims at providing consultancies for pharmaceutical companies to ultimately support the European legislation in bringing new drugs of a high ethical standard to the market and to exert a positive impact on the large population of patients suffering from rare diseases in Europe. The services provided by EuOrphan can facilitate concrete networking among patients, patient associations, doctors, and companies and also support the organization of clinical trials. In this perspective, EuOrphan could become a very valuable tool for globalizing the information about the availability of treatment (authorized or under development) of orphan patients.

Currently in Europe, approximately 30 million people suffer from rare diseases, and a major problem is that many patients do not have access to quality healthcare for their disorders. Moreover, there is also a lack of quality information and a networking system aimed at supporting interaction among patients, clinicians, researchers, pharmaceutical industries, and governmental bodies. The purpose of this article is to inform physicians, public health care professionals, and other health care providers about EuOrphan service, the aim of which is to ensure easier access to quality information on rare diseases and their treatment. A set of web-based services is available at www.euorphan.com where information for target-users on treatments and products available worldwide for rare disease care as well as indications about healthcare centers are provided. Moreover, the service aims at providing consultancies for pharmaceutical companies to ultimately support the European legislation in bringing new drugs of a high ethical standard to the market and to exert a positive impact on the large population of patients suffering from rare diseases in Europe. The services provided by EuOrphan can facilitate concrete networking among patients, patient associations, doctors, and companies and also support the organization of clinical trials. In this perspective, EuOrphan could become a very valuable tool for globalizing the information about the availability of treatment (authorized or under development) of orphan patients.

Currently in Europe, approximately 30 million people suffer from rare diseases, and a major problem is that many patients do not have access to quality healthcare for their disorders. Moreover, there is also a lack of quality information and a networking system aimed at supporting interaction among patients, clinicians, researchers, pharmaceutical industries, and governmental bodies. The purpose of this article is to inform physicians, public health care professionals, and other health care providers about EuOrphan service, the aim of which is to ensure easier access to quality information on rare diseases and their treatment. A set of web-based services is available at www.euorphan.com where information for target-users on treatments and products available worldwide for rare disease care as well as indications about healthcare centers are provided. Moreover, the service aims at providing consultancies for pharmaceutical companies to ultimately support the European legislation in bringing new drugs of a high ethical standard to the market and to exert a positive impact on the large population of patients suffering from rare diseases in Europe. The services provided by EuOrphan can facilitate concrete networking among patients, patient associations, doctors, and companies and also support the organization of clinical trials. In this perspective, EuOrphan could become a very valuable tool for globalizing the information about the availability of treatment (authorized or under development) of orphan patients.